Immuron says first patients enrolled in Campylobacter challenge clinical study

Immuron is pleased to announce that the US Naval Medical Research Command has initiated the clinical evaluation of a new oral therapeutic targeting Campylobacter and Enterotoxigenic Escherichia coli developed in collaboration with Immuron. The NMRC has prioritized the clinical development of the study to evaluate the efficacy of the new therapeutic product to prevent infectious diarrhea caused by Campylobacter. The dosing, challenge and the in-patient stage of the study is anticipated to be completed by the third week of December 2023. The estimated study completion date is June 2024 with headline results from the clinical trial expected to be reported in 2H 2024.